Avastone Consulting began working with GlaxoSmithKline (GSK) in 1992 with focus on building competitive capacity in the US market, and that work still continues. Subsequent mergers and integrations have since formed GSK, the world’s second largest research-based pharmaceutical company, operating in 37 countries with 85 manufacturing sites. Ensuring the organization could support that kind of growth and integration would be critical to their success.

Avastone Consulting has supported GSK in nearly every portion of the business including: sales and marketing, commercial operations, manufacturing, research and development, and corporate services groups.

Avastone provided development and transition services during both mergers: Glaxo–Burroughs Wellcome, and Glaxo Wellcome–SmithKline Beecham. GSK is the result of separate organizational successes transformed into an integrated success. If such integration is done well, a powerful entity can be created.

During our rich history with GSK, Avastone has conducted countless engagements in organizational development (assessments, targeted change interventions, team development processes) and executive development (individualized executive coaching and executive transition services) with the support of direct experience and simulations. Avastone’s continuity with key executives has been sustained over time, even as they have departed GSK for new organizations, where our coaching, development work, and support have continued.